Skip to content

Proton Radiotherapy for Recurrent Tumors

Retreatment of Recurrent Tumors Using Proton Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01126476
Enrollment
24
Registered
2010-05-19
Start date
2010-02-28
Completion date
2020-04-30
Last updated
2020-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumors

Keywords

Adults with non-CNS recurrent tumors who have been previously irradiated, and have a tumor recurrence in or near prior radiation fields

Brief summary

The purpose of this study is to determine the feasibility of using proton radiotherapy for reirradiation of recurrent malignancies.

Detailed description

Patients will be stratified by treatment site (Head and Neck, Thorax, Abdomen, Pelvis, Extremities) and by treatment volume (low volume, high volume) for a total of 10 strata. This study will be done in two phases. In the first phase, feasibility will be established using the primary objectives set below. The second phase will begin no earlier than 90 days after the last patient in the initial phase has completed treatment in each strata and once feasibility has been verified. The secondary objectives will serve as the objectives for the second phase of the study.

Interventions

Sponsors

Abramson Cancer Center at Penn Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with histologically confirmed, non-CNS solid malignancies who have been previously radiated and have a tumor recurrence in or near prior radiation fields. Re-biopsy of the recurrence is not required and left to the discretion of the treating physician, although every effort should be made to confirm recurrence. * Patients must have a Karnofsky Performance Status of 60. Life expectancy of 3 months . * Age greater or equal to 18. * Patients must be able to provide informed consent. * Women of child bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive, IUD, condoms or other barrier methods, etc.) * Hysterectomy or menopause must be clinically documented.

Exclusion criteria

* Prior radiation treatment less than 3 months from planned start of re-irradiation of any part of the intended treatment volume. * Pregnant women, women planning to become pregnant and women that are nursing. * Actively being treated on any research study.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of proton therapy90 daysTo determine if the study is infeasible, defined if greater than 10% of pts experience one of the following: 1. Patient cannot be given treatment because anatomy is such that a dosimetrically satisfactory treatment plan cannot be devised. 2. Patient who receives 15% or more of their treatments (for any reason, i.e. unable to set patient up within acceptable limits of tolerance, patient unable to tolerate treatment position or immobilization for duration of treatment) using photon radiotherapy (i.e. up to 15% of treatments could be delivered using photons). 3. Patient is unable to complete all of his/her treatments within 10 days of estimated date of treatment completion or requires a treatment break greater than 5 days.
Acute Toxicitywithin 90 daysAcute Toxicity is defined as any grade 4 toxicity observed within 90 days from the initiation of radiotherapy that is felt to be directly related to their proton treatment. Toxicities will be graded by NCI CTC Version 4.0

Secondary

MeasureTime frameDescription
Late toxicityopen-endedLate toxicity is defined as any grade 3 or higher toxicity observed later than 90 days from start of therapy. Late toxicities will be graded according to the RTOG/EORTC late morbidity scoring system.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026